Domain Therapeutics S.A.
Domain Therapeutics is a biopharmaceutical company located in
Strasbourg, France, dedicated to the discovery and early development
of small molecules targeting G-Protein Coupled Receptors (GPCRs),
one of the most important classes of drug targets. Domain
Therapeutics identifies and develops drug candidates using its DTect-All
(TM) innovative proprietary technology. The company’s portfolio is
composed of new chemical entities ranging from hits to optimized
leads for leading indications such as schizophrenia, Parkinson's
disease and diabetes.